Core Insights - Midea Group's medical segment, through its subsidiary Wandong Medical, has initiated a strategic cooperation with the Chinese Academy of Sciences' Electrical Engineering Research Institute to focus on high-field, helium-free magnetic resonance technology [1][2] - The collaboration aims to achieve a "1+1>2" effect by integrating industry needs with scientific innovation, contributing to the advancement of high-end medical equipment in China [1] - Wandong Medical is recognized as a leading enterprise in medical imaging in China, with a comprehensive industrialization system and advanced independent technology matrix [2] Company Overview - Wandong Medical has established a mature industrialization system covering core areas such as system design integration, software development, spectrometer manufacturing, and sequence reconstruction [2] - The company has extensive experience in managing national-level research and demonstration projects and has undertaken multiple national projects, including the "AI+Health" initiative [2] - Wandong Medical's products have been included in Beijing's major technology equipment directory and have received "three new" certifications, showcasing its full-chain capabilities in magnetic resonance system research, manufacturing, and industrialization [2] Strategic Goals - The partnership will focus on joint efforts in high-field, helium-free magnetic resonance technology, aiming to efficiently translate laboratory results into clinical products [2] - The collaboration seeks to establish a synergistic system encompassing "technology research and development—result transformation—clinical application—industry promotion" [2]

Core Viewpoint - WanDong Medical's stock has shown a mixed performance in recent trading, with a year-to-date increase of 16.57% but a decline in the last five and twenty trading days [1][2]. Financial Performance - For the first half of 2025, WanDong Medical reported revenue of 843 million yuan, representing a year-on-year growth of 20.46% [2]. - The company's net profit attributable to shareholders was approximately 51.30 million yuan, reflecting a significant year-on-year decrease of 39.46% [2]. Stock Market Activity - As of October 15, WanDong Medical's stock price was 17.45 yuan per share, with a market capitalization of 12.27 billion yuan [1]. - The stock experienced a trading volume of 54.59 million yuan and a turnover rate of 0.45% [1]. - The net inflow of main funds was 2.95 million yuan, with significant buying activity from large orders [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 11.69% to 26,800, while the average number of circulating shares per person increased by 13.24% to 26,201 shares [2][3]. - The top three circulating shareholders include HuaBao ZhongZheng Medical ETF, which increased its holdings, and Hong Kong Central Clearing Limited, which reduced its holdings [3].

证券代码：600055 证券简称：万东医疗 公告编号：临2025-046 登录新浪财经APP 搜索【信披】查看更多考评等级 一、回购股份的基本情况 2025年8月22日，北京万东医疗科技股份有限公司（以下简称"公司"）召开第十届董事会第十次会议， 审议通过《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交 易方式回购公司股份，用于员工持股计划或股权激励，回购股份金额为人民币3,000万元（含）-6,000万 元（含），回购股份价格不超过人民币25元/股，实施期限为自公司第十届董事会第十次会议审议通过 本次回购方案之日起12个月内。具体内容详见公司于2025年8月23日在上海证券交易所网站披露的《万 东医疗关于以集中竞价交易方式回购股份方案的公告》（公告编号：临2025-038）。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》等相关 规定，现将公司回购股份情况公告如下： 截至2025年10月9日，公司通过集中竞价交易方式累计回购股份281,200股，已回购股份占公司总股本的 比例为0.04%，购买的最高价为17.99 ...

格隆汇10月9日丨万东医疗(600055.SH)公布，截至2025年10月9日，公司通过集中竞价交易方式累计回 购股份281,200股，已回购股份占公司总股本的比例为0.04%，购买的最高价为17.99元/股、最低价为 17.65元/股，已支付的总金额为4,998,291元（不含交易费用）。 ...

证券代码：600055 证券简称：万东医疗 公告编号：临 2025-046 北京万东医疗科技股份有限公司 一、 回购股份的基本情况 关于股份回购进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/8/23 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 8 月 8 | 22 | 日~2026 | 年 | 月 | 21 日 | | 预计回购金额 | 3,000万元~6,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 281,200股 | | | | | | | 累计已回购股数占总股本比例 | 0.04% | | | | | | | 累计已回购金额 | 4, ...

万东医疗公告，截至2025年10月9日，公司通过集中竞价交易方式累计回购股份28.12万股，占公司总股 本的比例为0.04%，购买的最高价为17.99元/股、最低价为17.65元/股，已支付的总金额为499.83万元 （不含交易费用）。本次回购股份符合相关法律法规的规定和回购股份方案的要求。公司计划使用自有 资金以集中竞价交易方式回购公司股份，用于员工持股计划或股权激励，回购股份金额为人民币3000万 元（含）-6000万元（含），回购股份价格不超过人民币25元/股，实施期限为自公司第十届董事会第十 次会议审议通过本次回购方案之日起12个月内。 ...

Core Points - The company completed the grant registration of the 2025 stock option incentive plan on September 26, 2025, with a total of 1.16 million stock options granted to 13 eligible participants [1][2][7] - The stock options have a maximum validity period of 60 months, with different waiting periods of 12, 24, and 36 months for various grants [2][3] - The exercise price for the stock options is set at 15.05 yuan per option [3] Grant Details - The stock options were granted to 13 individuals, with one participant voluntarily waiving their entitlement [1][2] - The performance assessment for the stock options is based on company revenue and R&D investment rates over the fiscal years 2025 to 2027 [5] - Individual performance assessments will also influence the exercise ratio of the stock options, categorized into five levels: S, A, B, C, D [6] Financial Impact - The company will use the Black-Scholes model to calculate the fair value of the stock options, and adjustments will be made based on the number of exercisable options and performance metrics at each balance sheet date [7][8] - The total expenses related to the stock option incentive will be amortized and finalized based on the annual audit report from the accounting firm [8]

证券日报网讯 9月29日晚间，万东医疗发布公告称，根据有关规定，公司于2025年9月26日完成了2025 年股票期权激励计划预留股票期权的授予登记工作。股票期权授予登记完成时间：2025年9月26日；股 票期权授予登记数量：116万份；股票期权授予登记人数：13人。 （编辑 任世碧） ...

北京万东医疗科技股份有限公司 关于 2025 年股票期权激励计划 预留部分授予结果的公告 证券代码：600055 证券简称：万东医疗 编号：临 2025-045 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 5、股票来源：公司向激励对象定向发行的本公司人民币 A 股普通股股 票。 6、激励对象名单及授予情况 重要内容提示： 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、上 海证券交易所、中国证券登记结算有限责任公司上海分公司的有关规定，北 京万东医疗科技股份有限公司（以下简称"公司"）于2025年9月26日完成 了2025年股票期权激励计划预留股票期权的授予登记工作。现将相关内容公 告如下： 一、股票期权授予的具体情况 2025年8月22日，公司召开第十届董事会第十次会议，审议通过了《关于 向2025年股票期权激励计划激励对象预留授予股票期权的议案》，鉴于1名激 励对象自愿放弃，本次预留股票期权实际向符合条件的13名激励对象授予股 票期权116万份。 本次实际授予情况如下： 股票期权授予登记完成时间：202 ...

Group 1 - The company has approved a share repurchase plan using its own funds, with a total amount ranging from RMB 30 million to 60 million, and a maximum repurchase price of RMB 25 per share, to be executed within 12 months [1] Group 2 - As of September 25, 2025, the company has repurchased 281,200 shares, representing 0.04% of the total share capital, with a total expenditure of RMB 4,998,291, excluding transaction fees [2] Group 3 - The company will continue to make repurchase decisions based on market conditions and will fulfill its information disclosure obligations regarding the progress of the share repurchase [3]